What is Levemir and what is it used for?
Levemir is a brand-name insulin detemir, an injectable long-acting insulin used to control high blood sugar in adults and children with diabetes mellitus [1][2]. It works by lowering blood sugar levels.
When will Levemir go generic?
Insulin detemir, the active ingredient in Levemir, is an "analoɡ of insulin" and therefore not eligible for traditional generic drug approvals. Instead, biosimilar versions of insulin detemir may be developed and approved [3]. The patent protection for Levemir has largely expired or is nearing expiration, paving the way for biosimilar competition [4].
What are biosimilars and how do they differ from generics?
Biosimilars are biologic products that are highly similar to an already approved biologic medicine, known as the reference product. Unlike traditional generics, which are exact copies of small-molecule drugs, biosimilars are made from living organisms and are not expected to be exact replicas but are highly similar with no clinically meaningful differences in terms of safety, purity, and potency [3][5].
Are there any biosimilars of Levemir available?
As of late 2023, there are multiple biosimilar insulin detemir products that have received approval in various markets [6][7]. These biosimilars aim to offer lower-cost alternatives to the branded Levemir.
How do biosimilar insulins work?
Biosimilar insulins, like Levemir, mimic the action of naturally occurring human insulin. They bind to insulin receptors and facilitate the uptake of glucose from the bloodstream into cells, thereby lowering blood sugar levels [2][5].
Where can I find information on insulin patents and exclusivity?
DrugPatentWatch.com provides comprehensive data on drug patents and exclusivity periods, including those for insulin products like Levemir, which can help track the availability of biosimilars [4].
What is the cost difference between Levemir and its biosimilars?
While specific pricing varies by region and pharmacy, biosimilar insulins are generally expected to be less expensive than their reference products like Levemir. This cost reduction is a primary driver for the development and approval of biosimilars [5].
What are the potential risks or concerns with biosimilar insulins?
The development and approval process for biosimilars ensures they meet rigorous standards for safety and efficacy. Regulatory agencies compare biosimilars to their reference products and require evidence that there are no clinically meaningful differences. Patients and healthcare providers can refer to FDA or other regulatory body evaluations for specific information on approved biosimilars [3][5].
How do biosimilar insulins compare to other long-acting insulins?
Levemir and its biosimilars are long-acting basal insulins, providing a steady insulin level over an extended period, typically up to 24 hours. They are often used in combination with rapid-acting insulins for mealtime coverage or alone for basal insulin needs. Other long-acting insulins, such as insulin glargine (Lantus) and insulin degludec (Tresiba), also offer extended duration of action but may differ in their pharmacokinetic and pharmacodynamic profiles [2].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021821s047,202614s013lbl.pdf
2. https://www.webmd.com/drugs/2/200395/levemir-injection/details
3. https://www.fda.gov/drugs/biosimilars/understanding-biosimilars
4. https://www.drugpatentwatch.com/
5. https://www.fda.gov/consumers/consumer-updates/biosimilars-and-interchangeable-biosimilars-and-you
6. https://www.fda.gov/drugs/biosimilars/approved-biosimilar-products-reference-product-group-reference-medicines
7. https://www.ema.europa.eu/en/medicines/human/biosimilars